Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

BACKGROUND: Plasma exposure of sunitinib shows large inter-individual variation. Therefore, a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib dosing based on PK levels. METHODS: Patients were treated with sunitinib 37.5 mg once daily. At days 15 and 29 of tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021528/
https://www.ncbi.nlm.nih.gov/pubmed/24736581
http://dx.doi.org/10.1038/bjc.2014.194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021528/
https://www.ncbi.nlm.nih.gov/pubmed/24736581
http://dx.doi.org/10.1038/bjc.2014.194

Ejemplares similares